163 results about "Intestinal motility" patented technology

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

Compound of the formula (I):wherein Ar is a group of the following formula (Ar-1) or (Ar-2):A is a group of the formula:oror a pharmaceutically acceptable acid addition salt thereof, a process for preparing the same, a pharmaceutical composition containing the same, and intermediates therefor. The compounds of the present invention show a potent affinity for 5-HT4 receptors, and they are useful as a gastrointestinal motility enhancer or a gastrointestinal prokinetic agent.

A system and method may analyse and display intestinal motility events, based on an image stream captured by an in vivo imaging device. According to some embodiments, the system includes a storage unit to store image frames from the image stream, a processor to select a strip of pixels from a plurality of image frames of the image stream and to align the selected strips adjacently to form a motility events bar, and a visual display unit for displaying the motility events bar to a user.

The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.

The invention provides compounds of Formula (I)

or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R¹ are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.

The invention relates to a device for measuring the intestinal motility, that comprises a solid marker intended for travelling along the entire digestive system of a living being, or a portion thereof, a detector including means for detecting the position and the orientation of the marker, means for measuring the intestinal motility connected to the detector, wherein the marker and the detector includes transmission means and reception means for transmitting and receiving electromagnetic signals that ensure a bi-directional communication between the marker and the detector. The invention also relates to the use of the above-mentioned device.

This invention relates to a solid pharmaceutical composition that include a regulating agent of digestive and/or intestinal motility which has an agonist effect on peripheral μ, δ and κ opiate receptors; and an antiflatulent for the treatment and regulation of intestinal motility and flatulence in mammals. More in particularly, the pharmaceutical composition includes: (a) at least a regulating agent of intestinal motility such as trimebutine; (b) at least an antiflatulent such as simethicone; (c) at least a flowability promoter; (d) one or more lubricant; (e) at least an extender/diluent; (f) at least a disintegrant; and, (g) at least a binder.

A capsule for detection of gastrointestinal motility and a method for preparing such a capsule is provided. The capsule comprises a capsule enclosure and a preset quantity of radiopaque markers filled in the capsule. The radiopaque markers further comprise a solid X-ray contrast agent, a medical plastic with a density of at most at 1.4 g/cm³ and an auxiliary agent.

The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1 -Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-1-Fc fusion are useful in treating diabetes, obesity, initable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.

Non-invasive and/or natural orifice procedures, apparatus and methods for modulating the enteric nervous system using one or more energy modalities. A system may include a probe for insertion into a natural orifice (e.g., nasogastrically, orogastrically, nasojejunally) with or without a tube to therapeutically apply energy to modulate one or more portions of the enteric nervous system. The methods described herein may provide energy to stimulate the enteric nervous system to treat disorders such as irritable bowel syndrome, constipation, depression, anxiety and/or to enhance gastric motility, intestinal motility or other neurological responses.

The invention relates to a yacon fruit extract (Smallanthus sonchifolius fruit extract) and extraction method and application thereof. The extraction method comprises the following steps: (1) harvesting yacon fruits, washing or peeling, mixing with a protective agent at a ratio of 100:(1-10), blending, filtering, washing the filter cake with the protective agent for 2-3 times, and mixing the filtrates; (2) concentrating or drying the mixed filtrate and drying the filter cake; (3) dispersing dried filter cake in concentrated filtrate or dried product of filtrate, to obtain yacon fruit extract. The protective agent may be an acidic solution, a salt solution or a mixture thereof, or an inert gas. The yacon fruit extract has function of improving gastrointestinal functions, that is, function of reliving constipation. The fructooligosaccharide of yacon fruit extract is not absorbed by human body and has effects of cleaning blood, reducing blood lipid level and preventing hypercholesterolemia and diabetes. The yacon fruit extract can promote intestinal motility, reduce food intake and fat intake, promote defecation, reduce the absorption accumulation of lipids, promote lipid metabolism, and reduce weight gain.

The invention provides fiber type protein meal replacement powder. The fiber type protein meal replacement powder comprises the following components in parts by weight: 5-20 parts of wheat seedling powder, 23-40 parts of functional powdered sugar, 15-25 parts of comprehensive fruit powder, 20-30 parts of whey protein, 3-10 parts of resistance dextrin, 3-10 parts of konjac gum and 3-15 parts of comprehensive cereal vegetable powder. The invention further provides a preparation method of the fiber type protein meal replacement powder. The fiber type protein meal replacement powder is good in solubility, uniform, stable and fine and smooth in mouth feel, has high satiety, is suitable for being used as weight-reducing meal replacement powder, can meet requirements of human bodies for nutrition, can adjust microenvironment of the human bodies, can improve the gastrointestinal motility, and is a healthy food which is suitable for crowds being busy in ordinary life, lack of movement and need weight reduction to eat.

Disclosed herein are exendin singly modified with polyethylene glycole or a derivative thereof, a method for the preparation of the same, and uses thereof. Exendin modified at lysine (27) with polyethylene glycol shows biological activity similar to that of natural exendin, but is improved in half life. In addition, the modification position and the number of PEG or its derivative are restricted so as to minimize the side effects caused by a variety of combinations of such factors. The exendin is useful in the prevention and treatment of diseases caused by the over-secretion of insulin, or diseases caused due to a decrease in plasma glucose level, the inhibition of gastric or intestinal motility, the promotion of satiety, or the inhibition of food intake, especially diabetes, obesity and irritable colon syndrome.

The invention belongs to the field of drug screening and particularly relates to a method of creating a zebra fish peristalsis model and screening prokinetic medicaments. The method comprises the following steps of: (1) selecting the zebra fish; (2) inducing the model and treating the compound; (3) quantitatively analyzing through a fluorescence microscope. A fluorescent dye is applied in the invention for the first time to research the gastrointestinal peristalsis conditions, the new research method is a great complement for the existing research models, and the peristalsis model has important value in high throughput screening of the prokinetic compounds due to the maneuverability, non-invasion, simplicity and quickness.

Described are methods and composition for use in non-invasive imaging of intestinal structure and function. These methods can be used to identify, diagnose, assess, monitor and direct therapies for gastrointestinal diseases and disorders. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye excreted in bile into the intestinal tract to provide quantitative information regarding intestinal propulsion and function.

The present invention provides milk powder for improving resistance and promoting growth, and belongs to the technical field of milk powder. The milk powder comprises the following components in partsby mass: 25 to 35 parts of whole milk powder, 25 to 35 parts of demineralized whey powder, 16 to 25 parts of skimmed milk powder, 6-12 parts of isomalto-oligosaccharide, 3-6 parts of concentrated whey protein, 0.1-0.4 part of multivitamins, 0.3-0.8 parts of complex minerals, 0.12-0.25 part of docosahexaenoic acid, 0.12-0.25 part of arachidonic acid, 0.06-0.12 part of yeast beta-glucan, 0.01~0.02part of hydrolyzed egg yolk powder, 0 0.0-0.06 part of lutein, 0.008-0.015 part of N-acetylneuraminic acid and 0.03-0.06 part of probiotics. The milk powder can specifically improve growth ability, intellectual vision, intestinal motility and immunity, is nutritious and comprehensive, and has a pure milk flavor.